[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Boyd A, Cowie V, Gourley C: The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature. Int J Gynecol Cancer; 2009 Feb;19(2):273-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature.
  • BACKGROUND: Cervical cancer is one of the most frequently encountered malignancies in pregnancy.
  • CASE: A 26-year-old woman presented at 21 weeks gestation with a stage IIB high-grade clear cell cervical carcinoma.
  • CONCLUSION: Neoadjuvant cisplatin chemotherapy can be used in stage IIB cervical carcinoma during pregnancy to allow fetal development and prevent disease progression before delivery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Female. Fetal Development / drug effects. Humans. Pregnancy


2. Farré X, Guillén-Gómez E, Sánchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M: Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer; 2004 Dec 20;112(6):959-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.
  • Deoxynucleoside analogs are used in the treatment of a variety of solid tumors.
  • These 2 antisera, along with a previously characterized antibody that specifically recognizes the high-affinity Na-dependent concentrative NT, hCNT1, have been used to analyze, using a tissue array approach, NT expression in gynecologic cancers (90 ovarian, 80 endometrial and 118 uterine cervix carcinomas).
  • Human CNT1 was not detected in 33% and 39% of the ovarian and uterine cervix carcinomas, respectively, whereas hENT1 and hENT2 expression was significantly retained in a high percentage of tumors (91% and 96% for hENT1, 84% and 98% for hENT2, in ovarian and cervix carcinomas, respectively).
  • In ovarian cancer, the loss of all 3 NT proteins was a more common event in the clear cell histologic subtype than in the serous, mucinous and endometrioid histotypes.
  • In uterine cervix tumors, the loss of expression of hCNT1 was significantly associated with the adenocarcinoma subtype.
  • Moreover, NT expression is related to the type of gynecologic tumor and its specific subtype, hCNT1 protein loss being highly correlated with poor prognosis histotypes.
  • Since hCNT1, hENT1 and hENT2 recognize fluoropyrimidines as substrates, but with different affinities, this study anticipates high variability in drug uptake efficiency in solid tumors.
  • [MeSH-major] Carcinoma / chemistry. Equilibrative Nucleoside Transporter 1 / analysis. Equilibrative-Nucleoside Transporter 2 / analysis. Genital Neoplasms, Female / chemistry. Membrane Transport Proteins / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Antibodies, Neoplasm / analysis. Carcinoma, Endometrioid / chemistry. Carcinoma, Squamous Cell / chemistry. Cystadenocarcinoma, Serous / chemistry. Endometrial Neoplasms / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immune Sera. Ovarian Neoplasms / chemistry. Uterine Cervical Neoplasms / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15386342.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Equilibrative Nucleoside Transporter 1; 0 / Equilibrative-Nucleoside Transporter 2; 0 / Immune Sera; 0 / Membrane Transport Proteins; 0 / cif nucleoside transporter
  •  go-up   go-down


3. Cambruzzi E, Zettler CG, Alexandre CO: Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res; 2005;11(2):114-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma.
  • To estimate the association between human papillomavirus (HPV) status and the expression of p53, Ki-67 and bcl-2 in cases of endocervical adenocarcinoma, and the relation with squamous intraepithelial lesions (SIL) and age, 229 cases were selected, treated between 1995 and 2003 in the Hospital Nossa Senhora da Conceiçao.
  • The joint occurrence of endocervical adenocarcinoma and SIL were estimated too.
  • The mean age of the patients was 53.2 years, without clear correlation between age group and HPV (p=0.095).
  • The presence of HPV, especially type 18 in endocervical adenocarcinoma suggests that this agent can be an important cofactor in the development and progression of glandular neoplasms of the uterine cervix.
  • The joint occurrence of endocervical adenocarcinoma and SIL may support this hypothesis.
  • HPV may promote an increased proliferation index in endocervical adenocarcinoma, shown by the expression of Ki-67.
  • [MeSH-major] Adenocarcinoma / virology. Ki-67 Antigen / metabolism. Papillomaviridae / pathogenicity. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Proliferation. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cervix Uteri / virology. DNA, Viral / analysis. Female. Humans. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2003 Oct;82(10):960-5 [12956848.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):379-85 [8834311.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):577-82 [2554717.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):547-51 [13678722.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1079-85 [10613340.001]
  • [Cites] Int J Gynecol Pathol. 2002 Apr;21(2):125-33 [11917221.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):14-8 [12079293.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):209-16 [8600071.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1655-60 [12168850.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):129-36 [10739702.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):309-15 [9042795.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):1-6 [14668542.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):834-42 [15105176.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):5-13 [11836697.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):243-51 [10757335.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Histopathology. 2002 Oct;41(4):313-21 [12383213.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):420-2 [11874072.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):15-22 [12821336.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):176-80 [9071723.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):884-91 [11420459.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):265-70 [9989896.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):113-7 [9465813.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):68-72 [14693839.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):957 [9038727.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2297-303 [8635035.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1291-9 [11002225.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):160-6 [11319292.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):53-60 [10385551.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):238-46 [11531273.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Aug;82(8):762-6 [12848649.001]
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):49-53 [2703167.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):215-9 [12090589.001]
  • [Cites] Hum Pathol. 2000 Nov;31(11):1339-40 [11112206.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):95-103 [10393359.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):64-9 [8380284.001]
  • [Cites] Ann Med. 2003;35(7):458-65 [14649328.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):393-7 [9626509.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):22-7 [8986528.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • (PMID = 15999157.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


Advertisement
4. Treffers PE, Hanselaar AG, Helmerhorst TJ, Koster ME, van Leeuwen FE: [Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem]. Ned Tijdschr Geneeskd; 2001 Apr 7;145(14):675-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem].
  • [Transliterated title] Gevolgen van diëthylstilbestrol in de zwangerschap: na 50 jaar nog steeds een actueel probleem.
  • The most important consequences described are: for DES mothers an increased risk of mammary carcinomas and for DES daughters a 1 in 1000 chance of clear cell adenocarcinoma (CCAC) as well as an increased risk of (pre)malignant abnormalities of the stratified epithelium in the vagina and cervix.
  • In addition to this, DES daughters frequently have developmental disorders of the cervix and corpus uteri.
  • The DES problem continues to be an important issue.
  • The entire cohort of DES mothers is in the age group with a high risk of mammary carcinoma.
  • The incidence of CCAC of the vagina and cervix in the population is bimodal, with a second peak at older age.
  • From animal experiments it becomes clear that DES administration to pregnant mice results in an increased incidence of genital tumours not only in the second generation but also in the third.
  • The legally imposed destruction of patient files after a period of ten years is a serious threat to patient care and scientific investigation, notably in obstetrics and child medicine.
  • [MeSH-major] Adenocarcinoma, Clear Cell / epidemiology. Breast Neoplasms / epidemiology. Carcinogens / adverse effects. Diethylstilbestrol / adverse effects. Genital Neoplasms, Female / epidemiology. Genitalia / abnormalities. Medical Records / legislation & jurisprudence. Pregnancy Complications / epidemiology
  • [MeSH-minor] Adult. Animals. Female. Genital Diseases, Female / epidemiology. Humans. Incidence. Male. Mice. Middle Aged. Netherlands / epidemiology. Pregnancy. Prenatal Exposure Delayed Effects

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11530703.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 60
  •  go-up   go-down


5. Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ: Targeted therapies for rare gynaecological cancers. Lancet Oncol; 2010 Jul;11(7):685-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some gynaecological cancers are uncommon, such as sex cord-stromal tumours, malignant germ-cell tumours, vulvar carcinoma, melanoma of the female genital tract, clear-cell carcinoma of the ovary and endometrium, neuroendocrine tumours of the cervix, and gestational trophoblastic neoplasia.
  • All these cancers have different clinicopathological characteristics, suggesting different molecular biological pathogeneses.
  • Since these cancers are rare and large clinical trials are difficult to do, molecular biological techniques might allow rapid proof-of-principle experiments in few patients.
  • Novel targeted agents either alone or in combination with other treatments offer promising therapeutic options.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems / trends. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Female. Gestational Trophoblastic Disease / drug therapy. Humans. Melanoma / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neuroendocrine Tumors / drug therapy. Pregnancy. Sex Cord-Gonadal Stromal Tumors / drug therapy. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20362508.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


6. Kastritis E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P, Sarris K, Papadimitriou C, Dimopoulos MA: The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol; 2005 Nov;99(2):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.
  • BACKGROUND: Data about the outcome and prognostic factors in the group of patients with non-squamous cell advanced or recurrent carcinomas of the uterine cervix are limited.
  • We compared the outcome of patients with non-squamous with that of squamous cell carcinomas after platinum-based combination chemotherapy as first line therapy for stage IV or recurrent cervical carcinoma.
  • PATIENTS AND METHODS: A total of 200 patients with stage IV or recurrent carcinomas of the cervix received platinum-based combination chemotherapy and were included in our analysis.
  • RESULTS: There were 58 patients with non-squamous and 142 patients with squamous cell carcinomas.
  • CONCLUSION: Our study showed a similar outcome for both squamous and non-squamous stage IV or recurrent cervical carcinomas treated with platinum-based combination chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Cisplatin / administration & dosage. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Female. Humans. Middle Aged. Neoplasm Staging. Randomized Controlled Trials as Topic. Treatment Outcome


7. Sugiyama T, Ushijima K, Kamura T: [New regimens for the treatment of gynecologic cancers]. Gan To Kagaku Ryoho; 2000 Mar;27(3):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Japan, CPT-11/CDDP has been shown to be an effective and safe regimen in patients with advanced ovarian cancer, especially clear cell carcinoma and cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Taxoids. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Cisplatin / adverse effects. Clinical Trials, Phase II as Topic. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10740630.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin; CP protocol
  • [Number-of-references] 28
  •  go-up   go-down


8. Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ: Retinoids and ovarian cancer. J Cell Physiol; 2000 Oct;185(1):1-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the seventh most common cancer in women worldwide, after breast, cervix, colon/rectum, stomach, corpus uteri, and lung cancers.
  • Drug resistance is a common problem resulting in only 20 approximately 30% overall 5-year survival rates.
  • A number of recent studies have suggested that retinoids may play a potential role as an ovarian cancer chemotherapeutic agent.
  • This review will initially summarize what is known about the pathological and molecular characteristics of ovarian carcinoma.
  • It will then describe retinoid metabolism and the role of the cellular and nuclear retinoid binding proteins in mediating retinoid action.
  • Following this general review of retinoids and their function, data supporting the role of retinoic acid as a suppresser of ovarian carcinoma cell growth will be presented.
  • Particular attention will be paid to studies suggesting that members of the RB family of proteins and RB2/p130, in particular, are the molecular targets responsible for retinoid mediated inhibition of ovarian carcinoma cell growth.
  • It will be clear from the studies summarized in this review that retinoids represent a potentially powerful alternative to present chemotherapeutic approaches to the treatment of late stage ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Fenretinide / pharmacology. Fenretinide / therapeutic use. Ovarian Neoplasms / drug therapy. Retinoids / pharmacology. Retinoids / therapeutic use
  • [MeSH-minor] Cell Differentiation / drug effects. Cell Division / drug effects. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10942515.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI07101; United States / NCI NIH HHS / CA / CA64945; United States / NIDDK NIH HHS / DK / DK49045
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CD 437; 0 / Retinoids; 187EJ7QEXL / Fenretinide
  • [Number-of-references] 150
  •  go-up   go-down


9. Kokawa K, Umesaki N, Yamamoto K, Takizawa K, Konishi I, Hasegawa K, Japan Gynecologic Oncology Group: Phase I study of irinotecan combined with mitomycin-C and 5-fluorouracil for gynecological malignancies: the JGOG study. Anticancer Res; 2008 Sep-Oct;28(5B):2933-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A phase I study to evaluate combined therapy with irinotecan (CPT-11), mitomycin-C (MMC), and 5-fluorouracil (5-FU) was performed in patients with gynecological malignancy, especially non-squamous cell carcinoma of the uterine cervix.
  • MATERIALS AND METHODS: Eligibility for the study included patients with previously untreated, chemotherapy-naïve cervical and ovarian carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Ovarian Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Mucinous / drug therapy. Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031936.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement